Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
In brief, dual GLP-1/GIP receptor agonist might be more protective in crucial biomarkers of neurodegeneration in brain than a GLP-1 based agonist
For this reason, intravenous colchicine is very rarely used today
The Pros of GLP-1 for Weight Loss Significant Weight Loss: GLP-1 has consistently demonstrated impressive weight loss results, making it a viable option for those struggling with obesity
Liver-specific benefits of cotadutide have also been reported in T2D patients showing significantly reduced liver fat content by MRI-PDFF (magnetic resonance imaging-proton density fat fraction) as well as significant reductions in circulating collagen fragment, Pro-C3, as a biomarker for liver fibrosis activity and in the FIB4 index, a risk-factor score for fibrosis 11,12,56,57,58,59
Before starting GLP-1 medications: Ensure you've had a recent diabetic eye screening (within the past 12 months) Discuss your retinopathy status with your prescribing clinician If you have known retinopathy, consider ophthalmology review before initiation Understand that gradual dose titration may help avoid very rapid changes in blood glucose, which is a general principle in diabetes management During treatment: Attend all scheduled diabetic eye screening appointments without fail If you have pre-existing retinopathy, your diabetes team may consider more frequent monitoring based on your individual clinical situation Control blood pressure to target levels (below 140/90 mmHg, or below 130/80 mmHg if you have kidney, eye or cerebrovascular damage, if tolerated) [13] Maintain good overall glycaemic control whilst avoiding excessively rapid HbA1c reductions when possible Stop smoking if applicable, as tobacco significantly worsens diabetic eye disease Manage cholesterol levels according to NICE guidance for cardiovascular risk reduction Communicate openly with your healthcare team about any visual symptoms, even if they seem minor
[3] [4] The combined effect produces substantial weight losstypically about 15% of body weight over 68 weeks with semaglutide 2.4 mg (Wegovy), and up to 22% with tirzepatide 15 mg (Zepbound)
